In:
Oncology, S. Karger AG, Vol. 95, No. 2 ( 2018), p. 109-115
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) therapy has been recognized as the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring 〈 i 〉 EGFR 〈 /i 〉 mutations. However, resistance to EGFR-TKIs has been observed in certain subpopulations of these patients. We aimed to evaluate the impact of smoking history on the efficacy of EGFR-TKIs. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The records of patients ( 〈 i 〉 n = 〈 /i 〉 248) with NSCLC harboring activating 〈 i 〉 EGFR 〈 /i 〉 mutations who were treated with gefitinib or erlotinib at our institution between March 2010 and June 2016 were retrospectively reviewed, and the treatment outcomes were evaluated. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The overall response rate and median progression-free survival (PFS) were 59.7% and 10.7 months, respectively. The overall response rate was significantly higher in the ex- and nonsmokers than in the current smokers (64.6 vs. 51.1%, 〈 i 〉 p = 〈 /i 〉 0.038). PFS also differed significantly between the current smokers and the ex- and nonsmokers (12.4 vs. 7.4 months, 〈 i 〉 p = 〈 /i 〉 0.016). Multivariate analysis identified smoking history as an independent predictor of PFS and overall survival. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 〈 i 〉 〈 /i 〉 The clinical data obtained in this study provide a valuable rationale for considering smoking history as a predictor of the efficacy of EGFR-TKI in NSCLC patients harboring activating 〈 i 〉 EGFR 〈 /i 〉 mutations.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2018
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6